scholarly journals Initial application of a human laboratory model for estimating the motivational substitutability of e-cigarettes for combustible cigarettes.

2019 ◽  
Vol 27 (2) ◽  
pp. 125-135
Author(s):  
Adam M. Leventhal ◽  
Nicholas I. Goldenson ◽  
Claudia G. Aguirre ◽  
Jimi Huh ◽  
Matthew G. Kirkpatrick
Keyword(s):  
Laboratory Model ◽  
Initial Application ◽  
Human Laboratory

scholarly journals Developing and Validating a Human Laboratory Model to Screen Medications for Smoking Cessation

2012 ◽  
Vol 14 (11) ◽  
pp. 1362-1371 ◽  
Author(s):  
S. A. McKee ◽  
A. H. Weinberger ◽  
J. Shi ◽  
J. Tetrault ◽  
S. Coppola
Keyword(s):  
Smoking Cessation ◽  
Laboratory Model ◽  
Human Laboratory

scholarly journals Examining the effects of initial smoking abstinence on response to smoking-related stimuli and response inhibition in a human laboratory model

2013 ◽  
Vol 231 (10) ◽  
pp. 2145-2158 ◽  
Author(s):  
Matthew P. Bradstreet ◽  
Stephen T. Higgins ◽  
F. Joseph McClernon ◽  
Rachel V. Kozink ◽  
Joan M. Skelly ◽  
...  
Keyword(s):  
Response Inhibition ◽  
Laboratory Model ◽  
Smoking Abstinence ◽  
Human Laboratory

scholarly journals A novel human laboratory model for screening medications for alcohol use disorder

Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Diana Ho ◽  
Brandon Towns ◽  
Erica N. Grodin ◽  
Lara A. Ray
Keyword(s):  
Clinical Trials ◽  
Alcohol Use ◽  
Early Phase ◽  
Alcohol Use Disorder ◽  
Internal Validity ◽  
Laboratory Model ◽  
Phase 2 ◽  
Motivation To Change ◽  
Quit Attempt ◽  
Human Laboratory

Abstract Background Alcohol use disorder (AUD) is a highly prevalent, chronic relapsing disorder with a high disease burden in the USA. Pharmacotherapy is a promising treatment method for AUD; however, the few FDA-approved medications are only modestly effective. Medications development for AUD is a high priority research area, but the cumbersome drug development process hinders many potential compounds from reaching approval. One area with major opportunities for improvement is the process of screening novel compounds for initial efficacy, also known as early phase 2 trials. Early phase 2 trials incorporate human laboratory paradigms to assess relevant clinical constructs, such as craving and subjective responses to alcohol. However, these controlled paradigms often lack the ecological validity of clinical trials. Therefore, early phase 2 trials can be more efficient and clinically meaningful if they combine the internal validity of experimental laboratory testing with the external validity of clinical trials. To that end, the current study aims to develop and validate a novel early efficacy paradigm, informed by smoking cessation literature, to screen novel medications for AUD. As an established AUD medication, naltrexone will serve as an active control to test both the practice quit attempt model and the efficacy of a promising AUD pharmacotherapy, varenicline. Methods Individuals with current AUD reporting intrinsic motivation to change their drinking will complete a week-long “practice quit attempt” while on study medication. Participants are randomized and blinded to either naltrexone, varenicline, or placebo. During the practice quit attempt, participants will complete daily visits over the phone and fill out online questionnaires regarding their drinking, alcohol craving, and mood. Additionally, participants will undergo two alcohol cue-reactivity sessions. Discussion The successful completion of this study will advance medications development by proposing and validating a novel early efficacy model for screening AUD pharmacotherapies, which in turn can serve as an efficient strategy for making go/no-go decisions as to whether to proceed with clinical trials. Trial registration ClinicalTrials.gov NCT04249882. Registered on 31 January 2020.

scholarly journals Self-control depletion and nicotine deprivation as precipitants of smoking cessation failure: A human laboratory model.

2017 ◽  
Vol 85 (4) ◽  
pp. 381-396 ◽  
Author(s):  
Bryan W. Heckman ◽  
David A. MacQueen ◽  
Nicole S. Marquinez ◽  
James MacKillop ◽  
Warren K. Bickel ◽  
...  
Keyword(s):  
Smoking Cessation ◽  
Self Control ◽  
Laboratory Model ◽  
Nicotine Deprivation ◽  
Human Laboratory

Effect of the mGluR5 modulator GET 73 on alcohol pharmaco-kinetics and pharmacodynamics and alcohol craving in a human laboratory model

Alcohol ◽  
2017 ◽  
Vol 60 ◽  
pp. 225
Author(s):  
Robert Swift ◽  
Julia Wood ◽  
Jonathan Franco ◽  
Roberto Cacciaglia
Keyword(s):  
Laboratory Model ◽  
Alcohol Craving ◽  
Human Laboratory

scholarly journals Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse

2007 ◽  
Vol 197 (1) ◽  
pp. 157-168 ◽  
Author(s):  
Margaret Haney ◽  
Carl L. Hart ◽  
Suzanne K. Vosburg ◽  
Sandra D. Comer ◽  
Stephanie Collins Reed ◽  
...  
Keyword(s):  
Laboratory Model ◽  
Human Laboratory
Sign in / Sign up

Export Citation Format

Share Document